Lung and Bone Marrow Transplant for Pulmonary Fibrosis

Recruiting in Palo Alto (17 mi)

+1 other location

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Paul Szabolcs

Must not be taking: Live vaccines

Disqualifiers: Malignant conditions, HIV, Uncontrolled infections, others

No Placebo Group

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to understand any specific requirements.

What data supports the effectiveness of the treatment for Lung and Bone Marrow Transplant for Pulmonary Fibrosis?

Lung transplantation has been shown to be a successful treatment for patients with end-stage lung diseases, including pulmonary fibrosis, with survival rates of around 60% for single and double lung transplants. Additionally, lung transplants have been performed in patients with end-stage lung complications following hematopoietic stem cell transplantation, indicating potential effectiveness in combined treatments. ^{1 2 3 4 5}

Is the lung and bone marrow transplant treatment generally safe for humans?

Lung transplants and bone marrow transplants are complex procedures with potential risks. Lung transplants can lead to complications like infections and rejection of the new lung. Bone marrow transplants can cause serious issues such as infections, bleeding, and liver problems, and may lead to graft-versus-host disease, where the new marrow attacks the body. However, advances in medical care have reduced the frequency and severity of these complications. ^{5 6 7 8 9}

How is the Lung and Bone Marrow Transplant treatment for Pulmonary Fibrosis different from other treatments?

This treatment is unique because it combines lung transplantation with bone marrow transplantation, which is not a standard approach for pulmonary fibrosis. The combination aims to address both lung damage and potential underlying immune issues, offering a novel strategy for patients who may not benefit from lung transplantation alone. ^{1 2 10 11 12}

Research Team

Eligibility Criteria

This trial is for adults aged 18-60 with severe lung diseases like Pulmonary Fibrosis or COPD and bone marrow failure, who are eligible for a lung transplant. They must understand the study, not be pregnant, agree to birth control post-transplant, and have no allergies to stem cell product ingredients or recent live vaccines.

Inclusion Criteria

I have advanced lung disease like Pulmonary Fibrosis or COPD.

Patients must have low blood cell counts or abnormal blood tests that make them unsuitable for long-term treatment with immunosuppressive therapy. They must also meet at least one of the following criteria: low white blood cell counts, low platelet counts, or low red blood cell counts confirmed by repeat testing; normal kidney function and liver function; normal heart function; negative pregnancy test for females. If sexually active, patients must agree to use birth control. They will also be counseled about potential infertility risks and advised to consider sperm or egg freezing.

I am between 18 and 60 years old.

Exclusion Criteria

Inability or unwillingness of a participant to give written informed consent or comply with study protocol

I have a cancer diagnosis.

I am currently pregnant or breastfeeding.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Lung Transplantation

Participants undergo cadaveric, partially HLA-matched lung transplantation to restore pulmonary function

8 weeks

Multiple visits for pre-transplant evaluation and post-transplant monitoring

Bone Marrow Transplantation

Participants receive CD3+/CD19+ depleted bone marrow transplantation from the same donor to restore hematologic function

6 months

Regular visits for transplantation and monitoring

Follow-up

Participants are monitored for safety, effectiveness, and long-term complications after transplantation

Up to 2 years

Regular visits for monitoring immune tolerance and complications

Treatment Details

Interventions

• Alemtuzumab (Monoclonal Antibody)
• Bone Marrow Transplantation (Hematopoietic Stem Cell Transplantation)
• Fludarabine (Chemotherapy)
• G-CSF (Hematopoietic Growth Factor)
• Hydroxyurea (Chemotherapy)
• Lung Transplantation (Hematopoietic Stem Cell Transplantation)
• Rituximab (Monoclonal Antibody)
• Thiotepa (Chemotherapy)

Trial Overview The study tests if performing a lung transplant before a bone marrow transplant can restore lung function enough to proceed with bone marrow transplantation using various drugs (Rituximab, Alemtuzumab) and stem cells to improve blood cell counts.

Participant Groups

Group I: Lung and Bone Marrow Transplantation Experimental Treatment 7 Interventions

All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device. Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression. Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved.

Bone Marrow Transplantation is already approved in Canada, Japan, China, Switzerland for the following indications:

Approved in Canada as Bone Marrow Transplant for:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Aplastic Anemia
• Sickle Cell Disease
• Thalassemia
• Immune Deficiency Disorders

Approved in Japan as Bone Marrow Transplant for:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Aplastic Anemia
• Sickle Cell Disease
• Thalassemia
• Immune Deficiency Disorders

Approved in China as Bone Marrow Transplant for:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Aplastic Anemia
• Sickle Cell Disease
• Thalassemia
• Immune Deficiency Disorders

Approved in Switzerland as Bone Marrow Transplant for:

• Leukemia
• Lymphoma
• Multiple Myeloma
• Aplastic Anemia
• Sickle Cell Disease
• Thalassemia
• Immune Deficiency Disorders

Who Is Running the Clinical Trial?

Paul Szabolcs

Lead Sponsor

Trials

8

Recruited

230+

Findings from Research

The paper outlines the indications for various transplant procedures, including unilateral, bilateral, heart-lung, and lobar transplants, specifically for conditions like emphysema, cystic fibrosis, primary pulmonary hypertension, and pulmonary fibrosis.

It also provides a historical overview of these transplant procedures, highlighting their evolution and significance in treating severe lung diseases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Indications. Unilateral, bilateral, heart-lung, and lobar transplant procedures. Patterson, GA.[2019]

Single-lung transplantation (SLT) significantly reduces pulmonary artery pressure and improves oxygenation in patients with end-stage lung diseases and pulmonary hypertension, as shown by a study of 22 recipients over a period from 2002 to 2005.

Post-transplantation, systolic pulmonary artery pressure decreased from 50.00 mm Hg to 39.5 mm Hg, and the oxygenation index (PaO2/FiO2) improved from 241.26 mm Hg to 348.23 mm Hg, indicating the efficacy of SLT in enhancing respiratory function.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Single-lung transplantation for end-stage pulmonary parenchymal diseases with pulmonary hypertension]. Zhu, YH., Chen, JY., Zheng, MF., et al.[2007]

In a study of 128 lung transplant recipients, double lung transplants (DLT) showed significantly better 5-year survival rates (75%) compared to single lung transplants (SLT) (51%), highlighting the advantages of DLT for patients with end-stage lung diseases.

Patients with cystic fibrosis had the highest overall survival rates, with 87% reaching 1-year survival, while those with primary pulmonary hypertension had the lowest short-term survival, particularly after SLT, indicating that DLT is preferable for this group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Single Lung Transplant vs Double Lung Transplant: A Single-Center Experience With Particular Consideration for Idiopathic Pulmonary Arterial Hypertension. Antończyk, R., Stącel, T., Urlik, M., et al.[2020]

Lung transplantation has emerged as a viable treatment option for various pulmonary diseases, with three main types: single lung, double lung, and heart-lung transplants, each indicated for specific conditions.

Post-surgery management is crucial, focusing on immunosuppression therapy and monitoring for complications like graft rejection and obliterans bronchiolitis, which is a significant long-term concern.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Current status of lung transplantation]. García Río, FJ., García Talavera, I., Vázquez, M., et al.[2006]

Bone marrow transplant (BMT) is a preferred treatment for certain blood diseases, but it carries significant risks, including complications from the conditioning regimen like neutropenia and thrombocytopenia, which can lead to infections and bleeding.

Graft-versus-host disease (GVHD) is a common complication after allogeneic BMT, occurring when donor T cells attack the recipient's tissues, and patients require ongoing medical care for about a year post-transplant.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Post-bone marrow transplant patient management. Poliquin, CM.[2018]

Lung transplant is a critical procedure for patients with terminal and irreversible pulmonary diseases, with over 3,500 transplants performed in Spain, indicating its growing acceptance and application.

The review covers essential aspects of lung transplants, including types, indications, contraindications, procedures, and immunosuppressive treatments, highlighting the importance of understanding both the benefits and potential side effects of the procedure.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[What the family doctor must know about lung transplant (Part 1)]. Zurbano, L., Zurbano, F.[2018]

Bone marrow transplantation is a key treatment for conditions like aplastic anemia and severe combined immunodeficiency, but many patients lack compatible donors, highlighting the need for improved techniques.

Recent advances have reduced complications such as graft rejection and graft-versus-host disease, and using autologous stem cells may eliminate many issues associated with allogeneic transplants.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bone marrow transplantation in Canada. Buskard, NA.[2018]

References

1. United States pubmed.ncbi.nlm.nih.gov

Overview of Lung Transplantation, Heart-Lung Transplantation, Liver-Lung Transplantation, and Combined Hematopoietic Stem Cell Transplantation and Lung Transplantation. [2018]

2. United States pubmed.ncbi.nlm.nih.gov

Indications. Unilateral, bilateral, heart-lung, and lobar transplant procedures. [2019]

3. Switzerland pubmed.ncbi.nlm.nih.gov

[Status of lung transplantation: developments, indications and results]. [2006]

4. China pubmed.ncbi.nlm.nih.gov

[Single-lung transplantation for end-stage pulmonary parenchymal diseases with pulmonary hypertension]. [2007]

5. United States pubmed.ncbi.nlm.nih.gov

Single Lung Transplant vs Double Lung Transplant: A Single-Center Experience With Particular Consideration for Idiopathic Pulmonary Arterial Hypertension. [2020]

6. Spain pubmed.ncbi.nlm.nih.gov

[Current status of lung transplantation]. [2006]

7. United States pubmed.ncbi.nlm.nih.gov

Post-bone marrow transplant patient management. [2018]

8. Spain pubmed.ncbi.nlm.nih.gov

[What the family doctor must know about lung transplant (Part 1)]. [2018]

9. Canada pubmed.ncbi.nlm.nih.gov

Bone marrow transplantation in Canada. [2018]

10. United States pubmed.ncbi.nlm.nih.gov

Successful Single-Lung Transplant for Severe Lung Graft-Versus-Host Disease Two Years After Sibling Allograft for Acute Lymphoblastic Leukemia: A Case Report. [2018]

11. England pubmed.ncbi.nlm.nih.gov

Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. [2021]

12. United States pubmed.ncbi.nlm.nih.gov

Pulmonary transplant. Transplantation for end-stage lung disease: a nurse's perspective. [2007]